Field Trip Health Expands Access to Ketamine-Assisted Psychotherapy
Although based in Canada, the company is building a clinical network of therapists trained in ketamine-assisted psychotherapy across the United States.
Psychedelic Spotlight News
New Study Explores If Ayahuasca Changes Personality Like Other Psychedelics
Recent ayahuasca study concludes mixed messages in attempt to determine if the ancient plant medicine has power to change personality, as psilocybin has shown.
Revive Therapeutics Is Exploring This Mushroom’s Potential to Treat Aggressive Breast Cancer
The company is also pursuing psilocybin as a possible treatment for rare cancers, but they see huge potential in researching the medicinal effects of the reishi mushroom.
Interview with Evan Levine, PsyBio Therapeutics
In this episode of the Psychedelic Spotlight podcast, we spotlight Evan Levine, Chairman & CEO of PsyBio Therapeutics, an intellectual property driven biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health issues and other disorders.
Why PsyBio Is Using Biosynthetic Psilocybin, Not Mushrooms, to Build Better Therapeutics
“A mushroom is not a pharmaceutical product,” CEO Evan Levine stresses, and explains why his company’s method of biologically engineering psilocybin is “cheaper, faster, greener.”
Canada Green Lights Country’s Third Clinical Psilocybin Study
The trial will build on Diamond Therapeutic’s previous animal research that demonstrated how non-hallucinogenic doses of psilocybin hold the potential to treat psychiatric disorders, including anxiety and depression.
MindMed’s Q2 Earnings Call: What does the future hold for MNMD/ MMED?
Check out atai Life Sciences’ earnings call: https://www.youtube.com/watch?v=lkE3EmU0o_w
What’s up psychedelic stocks investors?!? Today marked MindMed’s (MNMD /MMED) Second Quarter 2021 conference call. In the conference call, MindMed gave updates on their varying projects, such as treating anxiety with LSD, addiction with 18MC, and pain with LSD. They also give insights into their digital medicines division and gave an update on their hiring spree.
This Kevin O’Leary-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 17+ different projects under their belt, MindMed is one of the most exciting companies to keep an eye on in the industry.
This conference call can help investors answer the questions: is MNMD stock a good investment? Will MMED go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Check out our website: thepsychedelicinvestor.com
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
#MindMed #MNMD #PsychedelicStocks
‘Have A Good Trip’ Director Donick Cary Prepares a Second Dose: ‘The Adventures Continue’
The filmmaker behind the Netflix hit tells us a sequel or a series is on the way, as well as which celebrities may share more psychedelic adventures.
Beckley Psytech Raises $80 Million to Fund Psychedelic Research Pipeline
The company will use proceeds of the fundraising round to complete its ongoing Phase 1B trial on low-dose psilocybin in patients suffering from a rare headache condition with no approved medications to treat it.
First Neuroimaging Study of Psilocybin Microdosing Underway in Sydney
Researchers hope to establish whether the effects of microdosing are as profound as people say they are, since previous studies could not rule out placebo effect.
End of content
End of content